# A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)

Study · id `cardio:ct-nct03496623` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03496623](<https://clinicaltrials.gov/study/NCT03496623>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03496623

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 188 participants.

## Technical summary

Registry record NCT03496623. Randomized; quadruple masking; primary purpose treatment. Start 2018-05-08 (actual); primary completion 2022-10-13 (actual). Results posted on 2023-11-24.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 188 participants (enrolled count; ClinicalTrials.gov record NCT03496623, source copy `cardio:ctgov-nct03496623-2023-11-24`, retrieved 2026-10-31)
- Started: 2018-05-08 (actual) (ClinicalTrials.gov record NCT03496623, source copy `cardio:ctgov-nct03496623-2023-11-24`, retrieved 2026-10-31)
- Primary completion: 2022-10-13 (actual) (ClinicalTrials.gov record NCT03496623, source copy `cardio:ctgov-nct03496623-2023-11-24`, retrieved 2026-10-31)
- Completion: 2022-10-13 (actual) (ClinicalTrials.gov record NCT03496623, source copy `cardio:ctgov-nct03496623-2023-11-24`, retrieved 2026-10-31)
- Results first posted: 2023-11-24 (ClinicalTrials.gov record NCT03496623, source copy `cardio:ctgov-nct03496623-2023-11-24`, retrieved 2026-10-31)
- Countries: United States; Argentina; Israel; Puerto Rico (ClinicalTrials.gov record NCT03496623, source copy `cardio:ctgov-nct03496623-2023-11-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03496623-2023-11-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
- Acronym: PERFECT
- Condition: Pulmonary Hypertension
- Condition: Chronic Obstructive Pulmonary Disease
- Intervention (Drug): Inhaled treprostinil solution
- Intervention (Drug): Placebo solution
- Lead sponsor: United Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: United Therapeutics (`cardio:org-united-therapeutics`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results (`cardio:pubmed-38811045`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 82f889d9249d0aae6e42851e796ba34f9e36fd7c3a90efa6aeef1fc6f55908b4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
